Mantle Ridge Releases Video Series Introducing Shareholder Nominees and Outlining Solutions for Challenges and Underperformance at Air Products and Chemicals, Inc.

Published on January 7, 2025

None of Mantle Ridge's affiliated entities is a hedge fund or other investment vehicle with a structurally short-term incentive. Mantle

Continue reading on website
Other news

Jeito Capital leads $67.5 million (€64.4 million[1]) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease

January 7, 2025
no treatment options.”About Jeito Capital Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach

Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials

January 7, 2025
of 2025. Upsized financing round led by a syndicate of top institutional investors, including Jeito Capital, only European fund within the